US · GILD · DRUG MANUFACTURERS - GENERAL
Gilead Sciences, Inc. (GILD) intrinsic value and stock valuation
$166.43as of 2026-11-21 · Mkt cap 165.39B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Gilead Sciences, Inc. DCF and intrinsic value
InvestorsCraft values GILD with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from GILD’s statements →
Gilead Sciences, Inc. Graham Number
Graham Number: $52.90d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Merck & Co., Inc. (MRK) $133.72
- Amgen Inc. (AMGN) $435.64
- Novo Nordisk A/S (NVO) $37.82
- Pfizer Inc. (PFE) $27.40
- Danaher Corporation (DHR) $220.36
- Bristol-Myers Squibb Company (BMY) $58.80
- Stryker Corporation (SYK) $310.00
- GSK plc (GSK) $47.76
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B |
| Operating income | $11.7B | $1.66B | $7.61B | $7.33B | $9.92B |
| Net income | $8.51B | $480M | $5.67B | $4.59B | $6.23B |
| EPSd | $6.78M | $382.5K | $4.5M | $3.64M | $4.93M |
| Operating cash flow | $10B | $10.8B | $8.01B | $9.07B | $11.4B |
| Capital expenditure | -$-563M | -$-523M | -$-585M | -$-728M | -$-579M |
| Free cash flow | $9.46B | $10.3B | $7.42B | $8.34B | $10.8B |
| Total assets | $59B | $59B | $62.1B | $63.2B | $68B |
| Total debt | $24.9B | $26.7B | $25B | $25.2B | $26.7B |
| Net debt | $17.4B | $16.7B | $18.9B | $19.8B | $21.4B |
| Total equity | $22.6B | $19.2B | $22.7B | $21.2B | $21.1B |
| Cash and short-term investments | $9.61B | $11.6B | $7.26B | $6.39B | $6.52B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B |
| Cost of revenue | $6.23B | $6.25B | $6.5B | $5.66B | $6.6B |
| Gross profit | $23.2B | $22.5B | $20.6B | $21.6B | $20.7B |
| Research and development expenses | $5.8B | $5.91B | $5.72B | $4.98B | $4.6B |
| Selling, general and administrative expenses | $5.71B | $6.09B | $6.09B | $5.67B | $5.25B |
| Other expenses | $0.00 | $8.84B | $1.21B | $3.64B | $939M |
| Operating expenses | $11.5B | $20.8B | $13B | $14.3B | $10.8B |
| Cost and expenses | $17.7B | $27.1B | $19.5B | $20B | $17.4B |
| Interest income | $349M | $281M | $376M | $106M | $0.00 |
| Interest expense | $1.02B | $977M | $944M | $935M | $1B |
| Depreciation and amortization | $2.76B | $2.77B | $2.69B | $2.1B | $2.05B |
| Ebitda | $13.6B | $4.43B | $10.5B | $8.85B | $11.3B |
| Operating income | $11.7B | $1.66B | $7.61B | $7.33B | $9.92B |
| Total other income/expenses, net | -$-1.91B | -$-972M | -$-746M | -$-1.52B | -$-1.64B |
| Income before tax | $9.8B | $690M | $6.86B | $5.81B | $8.28B |
| Income tax expense | $1.29B | $211M | $1.25B | $1.25B | $2.08B |
| Net income | $8.51B | $480M | $5.67B | $4.59B | $6.23B |
| Weighted average shares outstanding | $1.24B | $1.25B | $1.25B | $1.26B | $1.26B |
| Weighted average diluted shares outstanding | $1.26B | $1.26B | $1.26B | $1.26B | $1.26B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $9.61B | $11.6B | $7.26B | $6.39B | $6.52B |
| Net receivables | $4.91B | $4.42B | $4.66B | $4.78B | $4.49B |
| Inventory | $1.77B | $1.71B | $1.79B | $1.51B | $1.62B |
| Total current assets | $18.3B | $19.2B | $16.1B | $14.4B | $14.8B |
| Property, plant and equipment, net | $5.61B | $5.41B | $5.32B | $5.48B | $5.12B |
| Goodwill and intangible assets | $25.3B | $28.3B | $34.8B | $37.2B | $41.8B |
| Long-term investments | $2.97B | $0.00 | $1.16B | $1.25B | $1.31B |
| Total non-current assets | $40.7B | $39.8B | $46B | $48.7B | $53.2B |
| Total assets | $59B | $59B | $62.1B | $63.2B | $68B |
| Accounts payable | $715M | $833M | $550M | $905M | $705M |
| Short-term debt | $2.81B | $1.82B | $1.8B | $2.27B | $1.52B |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $11.8B | $12B | $11.3B | $11.2B | $11.6B |
| Long-term debt | $22.1B | $24.9B | $23.2B | $23B | $25.2B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $24.6B | $27.7B | $28.1B | $30.7B | $35.3B |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $36.4B | $39.7B | $39.4B | $42B | $46.9B |
| Common stock | $1M | $1M | $1M | $1M | $1M |
| Retained earnings | $13.7B | $11.5B | $16.3B | $15.7B | $16.3B |
| Accumulated other comprehensive income (loss) | $39M | $132M | $28M | $2M | $83M |
| Total equity | $22.6B | $19.2B | $22.7B | $21.2B | $21.1B |
| Total investments | $5.02B | $1.58B | $2.34B | $2.22B | $2.49B |
| Total debt | $24.9B | $26.7B | $25B | $25.2B | $26.7B |
| Net debt | $17.4B | $16.7B | $18.9B | $19.8B | $21.4B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $8.51B | $480M | $5.67B | $4.59B | $6.2B |
| Depreciation and amortization | $2.76B | $2.77B | $2.69B | $2.1B | $2.05B |
| Stock-based compensation | $894M | $835M | $766M | $644M | $635M |
| Change in working capital | -$-3.95B | -$-880M | -$-2.3B | -$-1.76B | $489M |
| Accounts receivable | -$-367M | $139M | $157M | -$-406M | $313M |
| Inventory | -$-1.04B | -$-426M | -$-842M | -$-310M | $11M |
| Accounts payable | -$-132M | $290M | -$-347M | $226M | -$-118M |
| Net cash provided by operating activities | $10B | $10.8B | $8.01B | $9.07B | $11.4B |
| Investments in property, plant and equipment | -$-563M | -$-523M | -$-585M | -$-728M | -$-579M |
| Acquisitions, net | -$-1.07B | -$-4.84B | -$-1.15B | -$-1.8B | -$-1.58B |
| Net cash used for investing activities | -$-4.79B | -$-3.45B | -$-2.27B | -$-2.47B | -$-3.13B |
| Common stock issued | $408M | $422M | $232M | $309M | $169M |
| Common stock repurchased | -$-1.92B | -$-1.15B | -$-1B | -$-1.4B | -$-546M |
| Dividends paid | -$-4B | -$-3.92B | -$-3.81B | -$-3.71B | -$-3.61B |
| Net cash used for financing activities | -$-7.75B | -$-3.43B | -$-5.13B | -$-6.47B | -$-8.88B |
| Net change in cash | -$-2.43B | $3.91B | $673M | $74M | -$-659M |
| Cash at end of period | $7.56B | $9.99B | $6.09B | $5.41B | $5.34B |
| Operating cash flow | $10B | $10.8B | $8.01B | $9.07B | $11.4B |
| Capital expenditure | -$-563M | -$-523M | -$-585M | -$-728M | -$-579M |
| Free cash flow | $9.46B | $10.3B | $7.42B | $8.34B | $10.8B |
Line items
Line items
Line items
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- CEO
- Daniel O'Day
- Employees
- 17K
- Beta
- 0.34
Included in
Explore
Frequently asked questions
What is the intrinsic value of Gilead Sciences, Inc. (GILD)?
Gilead Sciences, Inc. (GILD) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is GILD undervalued?
GILD trades at a price of $166.43 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.